EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2)

Daisuke Morinaga, Megumi Furuta, Satoshi Morita, Eisaku Miyauchi, Kunihiko Kobayashi, Makoto Maemondo, Hajime Asahina, North East Japan Study Group

Clinical Lung Cancer · 2025-12 · 26 (8) · 611-616

DOI: 10.1016/j.cllc.2025.08.012 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Lung Cancer, 2025-12. Verfasst von Daisuke Morinaga und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: AstraZeneca KK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In treatment-naïve advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, approximately 10% to 15% correspond to uncommon mutations. For patients with EGFR uncommon mutations, monotherapy with either a second-generation EGFR tyrosine kinase inhibitor (TKI), afatinib, or a third-generation EGFR-TKI, osimertinib, is recommended as the initial therapy. However, needs remain unmet for patients with central nervous system (CNS) metastases and those who do not respond adequately to single-agent TKI therapy for EGFR uncommon mutations. The recently published FLAURA2 trial showed that osimertinib in combination with platinum-pemetrexed significantly prolonged progression-free survival (PFS) and provided high disease control compared with osimertinib monotherapy for common mutations. Therefore, we planned this phase II study to evaluate the efficacy and safety of osimertinib in combination with platinum-pemetrexed in treatment-naïve NSCLC patients with EGFR uncommon mutations. PATIENTS AND METHODS: Forty patients will be enrolled in the study. The primary endpoint is the objective response rate, and the secondary endpoints include safety, PFS and overall survival in overall patients, patients with and without CNS lesions at baseline and according to mutation subtype. CONCLUSIONS: In this study, we will explore the efficacy and safety of osimertinib in combination with platinum-pemetrexed in treatment-naïve NSCLC patients with EGFR uncommon mutations. Our findings may provide treatment options for patients with EGFR uncommon mutations, especially those with CNS metastases or those requiring more intensive treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAniline CompoundsAcrylamidesLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMutationHumansPemetrexedErbB ReceptorsFemaleMaleMiddle AgedAgedAdultPlatinumClinical Trials, Phase II as TopicIndolesPyrimidines

Stichwörter der Autor:innen

ChemotherapyClinical trialCombination therapyEGFR mutationUncommon mutation

Substanzen

osimertinibAniline CompoundsAcrylamidesPemetrexedErbB ReceptorsEGFR protein, humanPlatinumIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
  • Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Tochigi, Japan.
  • Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan. Electronic address: asahinah@pop.med.hokudai.ac.jp.

Förderung

  • AstraZeneca KK

Zitieren

APA

Morinaga, D., Furuta, M., Morita, S., Miyauchi, E., Kobayashi, K., Maemondo, M., Asahina, H., & North East Japan Study Group (2025). A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2). Clinical Lung Cancer, 26(8), 611-616. https://doi.org/10.1016/j.cllc.2025.08.012

Vancouver

Morinaga D, Furuta M, Morita S, Miyauchi E, Kobayashi K, Maemondo M, et al. A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2). Clinical Lung Cancer. 2025;26(8):611-616. doi:10.1016/j.cllc.2025.08.012

BibTeX
@article{Morinaga2025,
  author = {Morinaga, Daisuke and Furuta, Megumi and Morita, Satoshi and Miyauchi, Eisaku and Kobayashi, Kunihiko and Maemondo, Makoto and Asahina, Hajime and North East Japan Study Group, North East Japan Study Group},
  title = {A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2)},
  journal = {Clinical Lung Cancer},
  year = {2025},
  volume = {26},
  number = {8},
  pages = {611--616},
  doi = {10.1016/j.cllc.2025.08.012}
}
Kostenlos starten →